Astrazeneca Plc (AZN)

AstraZeneca PLC (NYSE:AZN) is one of the best stem cell therapy stocks to buy. AstraZeneca PLC (NYSE:AZN) announced on April 21 that positive high-level results from a prespecified interim analysis of...

He stated that he is not surprised at the market resilience in the face of risk factors such as the war, oil prices, and inflation, looking at the behavior of the S&P 500 and the equity market more broadly...

The US economy is navigating a period of heightened volatility, defined by a sharp geopolitical tax on consumers and a resilient but stressed financial sector.

With the macroeconomic uncertainty looming over the market, the spotlight on institutional positioning gets brighter.

On March 24, Scott Chronert, Citi, appeared on CNBC’s 'Closing Bell' to talk about the market and whether it is time to get into equity markets.

UK equities have spent much of the past decade trading at a discount to US peers, often overlooked in favor of faster-growing U.S. markets.

AstraZeneca PLC (NASDAQ:AZN) is one of the most profitable blue chip stocks to invest in now.

AstraZeneca PLC (NYSE:AZN) is one of Goldman Sachs top healthcare stocks.

On March 12, Stephen Parker, JPMorgan Private Bank co-head of global investment strategy, appeared on CNBC’s ‘Squawk Box’ to talk about the latest market trends and the effects of the Iran war.